Stem Cell Clinic

AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States

By Global News Feed

LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces plans to launch its microRNA Signature Classifier (MSC) blood test for use in the more than 1.6 million US patients diagnosed each year with nodules as part of current lung cancer screening protocols. The company believes it will be able to further expand the use of the test to all of the 15 million at-risk patients who qualify for lung cancer screening annually in the US.

See the rest here:
AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

By Global News Feed

BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET.

Read the original here:
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral…

By Global News Feed

– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy volunteers –

See the original post here:
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,500 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the original:
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

By Global News Feed

SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company an $8 million grant to support its ongoing Phase 1/2a clinical trial of TRX103, an engineered Tr1 Treg cell therapy for use in the prevention of graft-versus-host disease (GvHD) in blood cancer patients undergoing mismatched stem cell transplants. This award follows a $4 million CIRM grant received by Tr1X in early 2024 for late-stage preclinical research that helped to advance TRX103 to human trials.

The rest is here:
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease

Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity

By Global News Feed

TAMPA, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, is pleased to announce that SRx Health Solutions, Inc. (“SRx Health”) has signed a definitive agreement to convert $4 million in debt to equity, improving SRx Health working capital position and future cash flow. This strategic investment was made by a strategic distribution partner to invest in the Company’s mission to deliver innovative, sustainable, and integrated healthcare solutions to patients in North America.

Continued here:
Better Choice Company Signs Definitive Agreement for SRx Health Solutions to Convert CAD$4 Million in Debt to Equity

NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

By Global News Feed

TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, Germany: J90) (“NurExone” or the “Company”) is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 3,543,238 units (“Units”) at a price of C$0.65 per Unit for aggregate gross proceeds of C$2,303,105 (the “Offering”). The Company intends to use the proceeds of the Offering for working capital, ExoTop’s establishment of a U.S. production facility and an uplisting to a major U.S. exchange, subject to requisite regulatory approval.

Here is the original post:
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

By Global News Feed

LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ: POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States.

Go here to see the original:
Renovaro Provides Update to Definitive Agreement with Predictive Oncology

→←